NCT07677072 Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
| NCT ID | NCT07677072 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kanuni Sultan Suleyman Training and Research Hospital |
| Condition | Osteoporosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 98 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 98 participants in total. It began in 2026-05-15 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria: * Female sex * Age 45 years or older * Postmenopausal status * Attendance at the Physical Medicine and Rehabilitation outpatient clinic * Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation * Ability and willingness to provide written informed consent Exclusion Criteria: Exclusion Criteria: * Premenopausal women * Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders) * Active infection or acute inflammatory disease * Major surgery within the previous 6 months * Neurological or muscular disorders that may significantly affect muscle function * Inability to comply with study procedures and assessments * Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents * Refusal or inability to provide written informed consent
Contact & Investigator
Dilek Ün oguzhanasiltürk, MD
PRINCIPAL INVESTIGATOR
Kanuni Sultan and Süleyman Training Resarch Hospital
Frequently Asked Questions
Who can join the NCT07677072 clinical trial?
This trial is open to female participants only, aged 45 Years or older, studying Osteoporosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07677072 currently recruiting?
Yes, NCT07677072 is actively recruiting participants. Contact the research team at dilekunoguzhan@gmail.com for enrollment information.
Where is the NCT07677072 trial being conducted?
This trial is being conducted at Küçükçekmece, Turkey (Türkiye).
Who is sponsoring the NCT07677072 clinical trial?
NCT07677072 is sponsored by Kanuni Sultan Suleyman Training and Research Hospital. The principal investigator is Dilek Ün oguzhanasiltürk, MD at Kanuni Sultan and Süleyman Training Resarch Hospital. The trial plans to enroll 98 participants.